share_log

Wedbush:重申Beam Therapeutics(BEAM.US)评级,由优于大市调整至优于大市评级, 目标价57.00美元。

Zhitong Finance ·  Apr 23 12:55

Wedbush:重申Beam Therapeutics(BEAM.US)评级,由优于大市调整至优于大市评级, 目标价57.00美元。

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment